|
Agreements (Details) (USD $)
|
12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 84 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Jul. 31, 2012
|
Dec. 31, 2012
Supply Agreement [Member]
|
Dec. 31, 2011
Supply Agreement [Member]
|
Dec. 31, 2010
Supply Agreement [Member]
|
Apr. 30, 2008
Research And Development Agreement [Member]
|
Jan. 31, 2002
Research And Development Agreement [Member]
|
Apr. 30, 2008
Research And Development Agreement [Member]
Minimum [Member]
|
Jan. 31, 2002
Research And Development Agreement [Member]
Minimum [Member]
|
Dec. 31, 2012
Employment Agreement [Member]
Minimum [Member]
|
Dec. 31, 2012
Employment Agreement [Member]
Maximum [Member]
|
Dec. 31, 2012
Astra Zeneca Agreement [Member]
|
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
|
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
|
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Maximum [Member]
Milestone Payments Based On Receipt Of Certain Regulatory Approvals And Initiation Of Commercial Sales Of Licensed Product [Member]
|
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
|
Dec. 31, 2012
Alseres Pharmaceuticals Inc [Member]
|
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Alseres Milestone Payments Based On Product Registration Or Commercial Sales [Member]
|
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Milestone Payments Maximum [Member]
|
Dec. 31, 2012
Cardiosonix [Member]
|
Dec. 31, 2012
Cardiosonix [Member]
Minimum [Member]
|
Dec. 31, 2012
Cardiosonix [Member]
Maximum [Member]
|
Dec. 31, 2012
Lymphoseek License Agreement [Member]
|
Dec. 31, 2011
Lymphoseek License Agreement [Member]
|
Dec. 31, 2010
Lymphoseek License Agreement [Member]
|
Dec. 31, 2012
Lymphoseek Expanded License Agreement [Member]
|
Dec. 31, 2011
Lymphoseek Expanded License Agreement [Member]
|
Dec. 31, 2010
Lymphoseek Expanded License Agreement [Member]
|
Jan. 31, 2006
Cira License Agreement [Member]
|
Dec. 31, 2012
Cira License Agreement [Member]
|
|
| Agreements [Line Items] | ||||||||||||||||||||||||||||||||
| Purchases under manufacture and supply agreement | $ 939,000 | $ 544,000 | $ 1,000,000 | |||||||||||||||||||||||||||||
| Purchase orders issued | 119,000 | |||||||||||||||||||||||||||||||
| License fee | 25,000 | 25,000 | 5,000,000 | 5,000 | ||||||||||||||||||||||||||||
| License maintenance fee | 25,000 | 25,000 | ||||||||||||||||||||||||||||||
| Royalty on net sales of licensed products , percentage | 5.00% | 5.00% | 3.00% | 5.00% | ||||||||||||||||||||||||||||
| Research and development | 16,890,482 | 15,154,365 | 8,941,046 | 14,000 | 5,000,000 | 1,800,000 | 33,000 | 98,000 | 36,000 | 31,000 | 28,000 | 27,000 | 100,000 | 100,000 | ||||||||||||||||||
| Common stock, shares issued | 113,018,772 | 95,398,961 | 300,000 | 950,000 | 1,150,000 | |||||||||||||||||||||||||||
| Contingent milestone payment | 2,900,000 | 6,500,000 | 6,500,000 | 11,000,000 | 2,500,000 | 2,900,000 | ||||||||||||||||||||||||||
| Royalty percentage on grant revenues | 300.00% | |||||||||||||||||||||||||||||||
| Royalty expense | 100,000 | 25,000 | 25,000 | 82,000 | 100,000 | |||||||||||||||||||||||||||
| Percentage of sublicense fees (royalties) | 50.00% | 50.00% | ||||||||||||||||||||||||||||||
| Accrued royalties | 1,000 | |||||||||||||||||||||||||||||||
| Maximum contingent liability | 3,100,000 | |||||||||||||||||||||||||||||||
| Ratio of entitled salary | 1.5 | 2.5 | ||||||||||||||||||||||||||||||
| Sublicense execution payment, cash paid | 175,000 | |||||||||||||||||||||||||||||||
| Grants received from Office of the Chief Scientist | $ 775,000 | |||||||||||||||||||||||||||||||